Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics, pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens.

Meeting the demand
for new antibiotics


A new class of antibiotics

Nabriva is focused on the development of pleuromutilins, a new class of antibiotics addressing a significant medical need.


Nabriva's lead product BC‑3781

BC‑3781 addresses significant medical needs, differentiated from all other agents and is about to enter Phase 3 studies.

Meet us at the
following conferences

ICAAC 2014

Sept 05 - 09, 2014
Washington DC, USA